Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, placebo-controlled phase 1a/b study of CB4211, a mitochondria based therapeutics (MBTs), in subjects with NASH and obesity with NAFLD.

Trial Profile

A double-blind, placebo-controlled phase 1a/b study of CB4211, a mitochondria based therapeutics (MBTs), in subjects with NASH and obesity with NAFLD.

Suspended
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs CB 4211 (Primary)
  • Indications Non-alcoholic steatohepatitis; Obesity
  • Focus Adverse reactions; Biomarker; First in man; Pharmacodynamics
  • Most Recent Events

    • 14 Nov 2018 According to a CohBar media release, the company is planning to share plans related to mild but persistent injection site reactions observed in the trial with the FDA and resume clinical activities as early as possible
    • 14 Nov 2018 Results published in the financial Media Release
    • 05 Nov 2018 Status changed from recruiting to suspended, as reported in a CohBar media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top